Abnormal formation of blood vessels is a common phenomenon in various solid tumors， particularly prominent in high-grade glioma. Multiple mechanisms have been discovered for formation of blood vessels， which promote the angiogenesis within tumor tissues and have been validated in high-grade glioma. Bevacizumab has been widely used in anti-angiogenic therapy for glioma， however， anti-angiogenic therapy still faces many problems. For example， the use of bevacizumab can improve the quality of life of patients and prolong their progression free survival. However， the overall survival of patients is not beneficial， and some patients do not show any imaging improvement after treatment. In addition， the issue of resistance to bevacizumab remains unresolved. Previous studies have suggested that the therapeutic resistance mechanisms can be mainly divided into two ways of promoting the malignant phenotype progression of tumor cells and promoting abnormal formation of blood vessels. These therapeutic resistance mechanisms may provide clues for enhancing the effectiveness of anti-angiogenic therapy and improving patient prognosis in the future.